A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
R E ColemanM Piccart

Abstract

One hundred and sixteen women with measurable metastatic breast cancer participated in a randomised phase II study of single agent liposomal pegylated doxorubicin (Caelyx) given either as a 60 mg/m2 every 6 weeks (ARM A) or 50 mg/m2 every 4 weeks (ARM B) schedule. Patients were over 65 years of age or, if younger, had refused or been unsuitable for standard anthracyclines. The aims of the study were to evaluate toxicity and dose delivery with the two schedules and obtain further information on the response rate of liposomal pegylated doxorubicin as a single agent in anthracycline nai ve advanced breast cancer. Twenty-six patients had received prior adjuvant chemotherapy (including an anthracycline in 10). Sixteen had received non-anthracycline-based first-line chemotherapy for advanced disease. One hundred and eleven patients were evaluable for toxicity and 106 for response. The delivered dose intensity (DI) was 9.8 mg/m2 (95% CI, 7.2-10.4) with 37 (69%) achieving a DI of >90% on ARM A and 11.9 mg/m2 (95% CI, 7.5-12.8) with 37 (65%) achieving a DI of >90% on ARM B. The adverse event profiles of the two schedules were distinctly different. Mucositis was more common with the every 6 weeks regimen (35% CTC grade 3/4 in ARM A, 14% ...Continue Reading

References


❮ Previous
Next ❯

Citations

Jan 26, 2007·Apoptosis : an International Journal on Programmed Cell Death·Leo L ChanBrian T Cunningham
Mar 23, 2011·Pharmaceutical Research·Ji Hoon JeongSun Hwa Kim
Jul 27, 2007·Cardiovascular Toxicology·Hernán Cortés-Funes, Cyntia Coronado
Oct 20, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AaproU Wedding
Jun 20, 2013·The Journal of Clinical Investigation·Stephen W JonesJames E Bear
Jul 13, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C Martín Sabroso, A I Torres-Suárez
Sep 1, 2007·Women's Health·M ShehataS Chan
Aug 22, 2014·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Timothy M ZagarMark W Dewhirst
Mar 28, 2008·Expert Review of Anticancer Therapy·Alessandro M MinisiniFabio Puglisi
Mar 13, 2009·Expert Opinion on Emerging Drugs·Omer Dizdar, Kadri Altundag
Oct 3, 2015·Drug Delivery·Siddartha Venkata TalluriSubbaRao V Madhunapantula
Aug 1, 2008·Expert Opinion on Drug Discovery·Brian T Cunningham, Lance G Laing
Jun 6, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C FalandryG Freyer
Jul 23, 2011·Journal of the American Academy of Dermatology·Yevgeniy BalagulaMario E Lacouture
May 27, 2011·Seminars in Oncology·Melody A Cobleigh
Feb 19, 2011·Cancer Treatment Reviews·Feng YangDeliang Fu
May 27, 2008·Clinical Lymphoma & Myeloma·Rebecca Soloman, Alberto A Gabizon
Dec 18, 2007·International Journal of Pharmaceutics·Tatsuhiro Ishida, Hiroshi Kiwada
Sep 5, 2006·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A NicoliniP Miccoli
Mar 12, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Roger von MoosAxel Hauschild
Sep 17, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E CurtitL Cals
Mar 25, 2014·The Breast : Official Journal of the European Society of Mastology·Arnoud J TempletonUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center
Oct 24, 2019·Anti-cancer Agents in Medicinal Chemistry·Sivakumar P MalliappanAbimanyu Sugumaran
Jan 8, 2020·International Journal of Women's Dermatology·Michelle N FerreiraJonathan S Leventhal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Cancer Cell Invasion: Nanomedicine

Nanomedicine is a promising alternative for cancer detection and therapy that utilizes nanoparticles, such as liposomes. Nanoparticles can potentially target cancer cell invasion and metastasis. Discover the latest research on Cancer Cell Invasion: Nanomedicine here.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.